Skip to main content
Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial

Fig. 4

Correlation between changes in estimated fluid volumes and NT-proBNP concentration. a Scatterplot detailing the correlation between percentage change from baseline to week 24 in ePV and corresponding change in log-transformed NT-proBNP concentration in the empagliflozin treatment group. b Scatterplot detailing the correlation between change from baseline to week 24 in eEV and corresponding change in log-transformed NT-proBNP concentration in the empagliflozin treatment group. The mean regression line (solid line) and 95% confidence intervals (broken line) are displayed. NT-proBNP N-terminal pro-brain natriuretic peptide. Others see Fig. 2

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840